IVF Hartmann Holding (VBSN) Fair Value & Analysis
Healthcare · CH · Market cap CHF 311M
Fair value as of: Jul 17, 2026
From 24 valuation models · updated 24 days ago
Fair value updated Jul 17, 2026, revised from CHF 133.85 to CHF 143.25 (+7.0%) since Jun 24, 2026. Share price −5.7% over the past month.
A solid business, screening 15% undervalued on our models.
What matters now
- Our model range runs from CHF 113.17 (bear) to CHF 177.90 (bull), base CHF 143.25. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 67/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range CHF 91.49 – CHF 165.96 · fair‑value band CHF 113.17 – CHF 177.90 · the CHF 125.00 price screens below the CHF 143.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
IVF Hartmann Holding (VBSN) currently trades at CHF 125.00, while our model-based Fair Value estimate is CHF 143.25, implying the stock looks roughly 14.6% undervalued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, IVF Hartmann Holding generated revenue of CHF 162M at a net margin of 11.3%. Revenue grew 2.6% year over year. It earns a return on equity of 11.9%. The balance sheet holds a net cash position of CHF 90.4M. Fundamentals as of Jul 17, 2026
Our scenario range runs from CHF 113.17 (bear case) to CHF 177.90 (bull case); at CHF 125.00, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 14% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 15%, VBSN screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Multiples (CHF 131.68) versus Asset-Based (CHF 43.73). Highest evidence: Residual Income (76).
Notify me when VBSN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 47
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
IVF Hartmann Holding AG provides medical consumer goods in Switzerland and internationally. The company offers medical devices; hygiene products, body care, hair care, and breast feeding aids; and disinfectants.
Full company description
IVF Hartmann Holding AG provides medical consumer goods in Switzerland and internationally. The company offers medical devices; hygiene products, body care, hair care, and breast feeding aids; and disinfectants. It also provides household items, including film products, hygiene papers, catering supplies, cleaning papers and textiles, and other household items. The company was formerly known as IVF and changed its name to IVF Hartmann Holding AG in 1993. The company was founded in 1870 and is headquartered in Neuhausen am Rheinfall, Switzerland. IVF Hartmann Holding AG operates as a subsidiary of Paul Hartmann Finance B.V.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
IVF Hartmann Holding reported revenue of CHF 162M in FY2025 versus CHF 144M in FY2021, a compound +2.9%/yr. Reported net income was CHF 18.3M in FY2025, compounding +31.0%/yr from FY2021.
of which total revenue +1.8 pp · buybacks/dilution −0.1 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch VBSN: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare IVF Hartmann Holding with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is IVF Hartmann Holding (VBSN) overvalued or undervalued?
What is the fair value of VBSN?
What is the quality score of VBSN?
What is the revenue of IVF Hartmann Holding (VBSN)?
What is the net profit margin of VBSN?
Does IVF Hartmann Holding pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track IVF Hartmann Holding and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.